image: <\/p>\n
Although the specificity of CRISPR-based gene-editing is highly accurate and versatile, the efficiency of installing those edits has been low. In this paper, the Adamson lab describes a more efficient prime editor. Illustration by Caitlin Sedwick for Princeton University. <\/p>\n
Credit: Caitlin Sedwick for Princeton University <\/p>\n
By Caitlin Sedwick for the Princeton University Department of Molecular Biology <\/p>\n
Through years of engineering gene-editing systems, researchers have developed a suite of tools that enable the modification of genomes in living cells, akin to genome surgery. These tools, including ones based on a natural system known as CRISPR\/Cas9, offer enormous potential for addressing unmet clinical needs, underscored by the recent FDA approval of the first CRISPR\/Cas9-based therapy. A relatively new approach called prime editing enables gene-editing with exceptional accuracy and high versatility, but has a critical tradeoff: variable and often low efficiency of edit installation. In other words, while prime edits can be made with high precision and few unwanted byproducts, the approach also often fails to make those edits at reasonable frequencies. In a paper that appeared in print in the journal Nature on April 18th, 2024, Princeton scientists Jun Yan and Britt Adamson, along with several colleagues, describe a more efficient prime editor. <\/p>\n
Prime editing systems minimally consist of two components: a modified version of the protein element of CRISPR\/Cas9 and a ribonucleic acid (RNA) molecule called a pegRNA. These components work together in several coordinated steps: First, the pegRNA binds the protein and guides the resulting complex to a desired location in the genome. There, the protein nicks the DNA and, using a template sequence encoded on the pegRNA, reverse transcribes an edit into the genome nearby. In this way, prime editors write exact sequences into targeted DNA. <\/p>\n
\"Prime editing is such an incredibly powerful genome editing tool because it gives us more control over exactly how genomic sequences are changed, Adamson said. <\/p>\n
At the outset of their study, Adamson and Yan, a graduate student in Adamsons research group and the Department of Molecular Biology, reasoned that unknown cellular processes may aid or hinder prime editing. To identify such processes, Yan laid out a conceptually simple plan: First, he would engineer a cell line that would emit green fluorescence when certain prime edits were installed. Then, he would systematically block expression of proteins normally expressed within those cells and measure editing-induced fluorescence to determine which of those proteins impact prime editing. By executing this plan, the team identified 36 cellular determinants of prime editing, only one of whichthe small RNA-binding protein Lapromoted editing. <\/p>\n
Although promoting prime editing is obviously not a normal function of the La protein, our experiments showed that it can strongly facilitate the process, Yan said. <\/p>\n
Within cells, La is known to bind specific sequences often found at the ends of nascent small RNA molecules and it protects those RNAs from degradation. The Princeton team recognized right away that the pegRNAs deployed in Yans first experiments likely contained those exact sequences, called polyuridine tracts, as they are a typical but often overlooked byproduct of pegRNA expression in cells. Subsequent experiments suggested that such pegRNAs inadvertently harness Las end-binding activity for protection and to promote prime editing. <\/p>\n
Motivated by their results, the team asked if fusing the part of La that binds polyuridine tracts to a standard prime editing protein could boost prime editing efficiencies. They were thrilled to find that the resulting protein, which they call PE7, substantially enhanced intended prime editing efficiencies across conditions and, when using some prime editing systems, left the frequencies of unwanted byproducts very low. Their results quickly drew the attention of colleagues interested in using prime editing in primary human cells, including Daniel Bauer at Boston Childrens Hospital and Harvard Medical School and Alexander Marson at the University of California, San Francisco. Together with scientists from these labs, the team of researchers went on to demonstrate that PE7 can also enhance prime editing efficiencies in therapeutically relevant cell types, offering expanded promise for future clinical applications. <\/p>\n
\"This work is a beautiful example of how deeply probing the inner workings of cells can lead to unexpected insights that may yield near-term biomedical impact, Bauer noted. <\/p>\n
Citation: Jun Yan, Paul Oyler-Castrillo, Purnima Ravisankar, Carl C. Ward, Sbastien Levesque, Yangwode Jing, Danny Simpson, Anqi Zhao, Hui Li, Weihao Yan, Laine Goudy, Ralf Schmidt, Sabrina C. Solley, Luke A. Gilbert, Michelle M. Chan, Daniel E. Bauer, Alexander Marson, Lance R. Parsons & Britt Adamson.Improving prime editing with an endogenous small RNA-binding protein.Nature. 2024. DOI: https:\/\/doi.org\/10.1038\/s41586-024-07259-6<\/a> <\/p>\n Funding for this work was provided by the National Institutes of Health (NIH) (R35GM138167, RM1HG009490, T32HG003284, DP2CA239597, UM1HG012660 [Princeton QCB training grant; NHGRI],and [T32GM007388 Princeton MOL training grant; NIGMS]); the Searle Scholars Program; thePrinceton Catalysis Initiative; CHDI Foundation; Princeton University; the Parker Institute for Cancer Immunotherapy (PICI); the Lloyd J. Old STAR award from the Cancer Research Institute (CRI); the Simons Foundation; the CRISPR Cures for Cancer Initiative; the Arc Institute; CRUK\/NIH (OT2CA278665 and CGCATF-2021\/100006); Pew-Stewart Scholars for Cancer Research award; the Doris Duke Foundation; the St Jude Childrens Research Hospital Collaborative Research Consortium; NHLBI (R01HL150669); the Fred Hutch Cooperative Center of Excellence in Hematology (U54 DK106829); the China Scholarship Council (CSC), based on the April 2015 Memorandum of Understanding between the CSC and Princeton University; the NCI (K00CA245718); and the Princeton University Flow Cytometry Resource Facility (NCI-CCSG P30CA072720-5921). <\/p>\n Experimental study <\/p>\n Improving prime editing with an endogenous small RNA-binding protein <\/p>\n 3-Apr-2024 <\/p>\n B.A. is an advisory board member with options for Arbor Biotechnologies and Tessera Therapeutics. B.A. holds equity in Celsius Therapeutics. L.A.G has filed patents on CRISPR tools and CRISPR functional genomics and is a co-founder of Chroma Medicine. A.M. is a co-founder of Arsenal Biosciences, Site Tx, Spotlight Therapeutics, and Survey Genomics, serves on the boards of directors at Site Tx, Spotlight Therapeutics and Survey Genomics, is a member of the scientific advisory boards of Arsenal Biosciences, Site Tx, Spotlight Therapeutics, Survey Genomics, NewLimit, Amgen, Tenaya, and Lightcast, owns stock in Arsenal Biosciences, Site Tx, Spotlight Therapeutics, NewLimit, Survey Genomics, PACT Pharma, Tenaya, and Lightcast, and has received fees from Arsenal Biosciences, Spotlight Therapeutics, Site Tx NewLimit, Survey Genomics, Gilead, 23andMe, PACT Pharma, Juno Therapeutics, Tenaya, Lightcast, Trizell, Vertex, Merck, Amgen, Genentech, AlphaSights, Rupert Case Management, Bernstein, GLG, ClearView Healthcare Partners, and ALDA. A.M. is an investor in and informal advisor to Offline Ventures and a client of EPIQ. The Marson Laboratory has received research support from Juno Therapeutics, Epinomics, Sanofi, GlaxoSmithKline, Gilead, and Anthem. C.C.W. and R.S. are co-founders of Site Tx. J.Y. and B.A. have filed a patent application on aspects of this work through Princeton University, and B.A. has previously filed other patents on CRISPR-based technologies. The remaining authors declare no competing interests. <\/p>\n Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system. <\/p>\n <\/p>\n More:<\/p>\n A small factor makes a big impact on genome editing - EurekAlert<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" image: Although the specificity of CRISPR-based gene-editing is highly accurate and versatile, the efficiency of installing those edits has been low. In this paper, the Adamson lab describes a more efficient prime editor. Illustration by Caitlin Sedwick for Princeton University Continue reading